The latest price target for Merck & Co (NYSE:MRK) was reported by UBS on April 13, 2026. The analyst firm set a price target for $145.00 expecting MRK to rise to within 12 months (a possible 25.39% upside). 34 analyst firms have reported ratings in the last year.

The latest analyst rating for Merck & Co (NYSE:MRK) was provided by UBS, and Merck & Co maintained their buy rating.

The last upgrade for Merck & Co Inc happened on January 8, 2026 when Wolfe Research raised their price target to $135. Wolfe Research previously had a peer perform for Merck & Co Inc.

The last downgrade for Merck & Co Inc happened on September 17, 2025 when Berenberg changed their price target from $100 to $90 for Merck & Co Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merck & Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merck & Co was filed on April 13, 2026 so you should expect the next rating to be made available sometime around April 13, 2027.

While ratings are subjective and will change, the latest Merck & Co (MRK) rating was a maintained with a price target of $130.00 to $145.00. The current price Merck & Co (MRK) is trading at is $115.64, which is out of the analyst’s predicted range.